<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835977</url>
  </required_header>
  <id_info>
    <org_study_id>2013249</org_study_id>
    <nct_id>NCT01835977</nct_id>
  </id_info>
  <brief_title>Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer</brief_title>
  <official_title>Multi-Center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Office of the Endourological Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Research Office of the Endourological Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centre Randomized Clinical Trial: 106 patients with confirmed unilateral high-volume&#xD;
      low risk (Gleason score 3 + 3) or intermediate risk prostate cancer (Gleason score 3 + 4)&#xD;
      will undergo an IRE treatment. These patients will be randomized into one of the two groups&#xD;
      of the study.&#xD;
&#xD;
      Group 1: Focal ablation of the prostate at the side of the positive biopsies (focal-ablation)&#xD;
      Group 2: Extended ablation of the prostate (extended ablation)&#xD;
&#xD;
      Patients will have an ultrasound of the prostate and the imaging data will be entered into&#xD;
      the Planning Software system of the IRE-device. The volume of the prostate is measured and a&#xD;
      specified ablation zone will be determined. The patients will be admitted for overnight stay&#xD;
      in the hospital on the morning of the scheduled IRE procedure. The IRE will be performed&#xD;
      under general anaesthetic and the specified zone identified in the planning stage will be&#xD;
      ablated. Two to four IRE electrode needles will be placed into the prostate under ultrasound&#xD;
      image guidance with a perineal approach using a brachytherapy grid. When the needles are in&#xD;
      place, electric pulses of one to two minutes duration are used to ablate the specified zone.&#xD;
      The total procedure time will be approximately 1 hour.&#xD;
&#xD;
      Safety data will be collected and patients will be followed up at 1 day post-operatively, 1&#xD;
      month, 3 months, 6 months and 1, 2 and 3 year(s) post IRE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient experience (side-effects and quality of life) after IRE ablation of prostate cancer</measure>
    <time_frame>5 years</time_frame>
    <description>To determine post procedural side-effects and Quality of life measured by International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF) and Functional Assessment of Cancer Therapy-Prostate (FACT-P).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oncological efficacy IRE ablation of prostate cancer.</measure>
    <time_frame>5 years</time_frame>
    <description>To determine if IRE focal ablation procedure is as effective as extended ablation measured by PSA, standardised transrectal biopsies and MRI findings in follow-up.&#xD;
To determine accurateness of ablation zone detection by MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Focal ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Irreversible Electroporation (Nanoknife)</intervention_name>
    <arm_group_label>Extended ablation</arm_group_label>
    <arm_group_label>Focal ablation</arm_group_label>
    <other_name>Nanoknife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Histologically confirmed organ-confined unilateral prostate cancer with adjacent&#xD;
             positive biopsies on transperineal template prostate biopsies or MRI targeted biopsies&#xD;
             in combination with systematic biopsies (clinical stage T1c-T2b)&#xD;
&#xD;
          2. Gleason sum score 6 or 7&#xD;
&#xD;
          3. PSA &lt;15 ng/ml or PSA &gt; 15 ng/mL counselled with caution&#xD;
&#xD;
          4. Life expectancy of &gt; 10 years&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Bleeding disorder as determined by prothrombin time (PT) &gt; 14.5 seconds, partial&#xD;
             thromboplastin time (PTT) &gt; 34 seconds, and Platelet Count &lt; 140/uL&#xD;
&#xD;
          2. No ability to stop anticoagulant or anti-platelet therapy for 7 days prior the&#xD;
             procedure.&#xD;
&#xD;
          3. Active urinary tract infection (UTI)&#xD;
&#xD;
          4. History of bladder neck contracture&#xD;
&#xD;
          5. Anaesthesia Surgical Assignment category IV or greater&#xD;
&#xD;
          6. History of inflammatory bowel disease&#xD;
&#xD;
          7. Concurrent major debilitating illness&#xD;
&#xD;
          8. Prior or concurrent malignancy except for basal cell carcinoma of the skin&#xD;
&#xD;
          9. Cardiac history including arrhythmias, ICD or pacemaker&#xD;
&#xD;
         10. Prostate calcifications greater than 5 mm.&#xD;
&#xD;
         11. Biologic or chemotherapy for prostate cancer&#xD;
&#xD;
         12. Hormonal therapy for prostate cancer within 6 months prior to procedure&#xD;
&#xD;
         13. Previous radiation to pelvis&#xD;
&#xD;
         14. Transurethral resection of the prostate / Urethral stent&#xD;
&#xD;
         15. Prior major rectal surgery (except haemorrhoids)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean de la Rosette, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Research Office of the Endourological Society</affiliation>
  </overall_official>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.croesoffice.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Focal therapy</keyword>
  <keyword>Irreversible electroporation</keyword>
  <keyword>Unilateral prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

